Brexpiprazole Uses
Brexpiprazole is FDA-approved for two specific indications: (1) adjunctive treatment of major depressive disorder (MDD) in adults when added to antidepressants, and (2) treatment of schizophrenia in adults. 1
FDA-Approved Indications
1. Adjunctive Treatment of Major Depressive Disorder
- Used as an add-on therapy to antidepressants in adults with inadequate response to antidepressant monotherapy 1
- Dosing: Start at 0.5-1 mg daily, titrate weekly to target dose of 2 mg daily (maximum 3 mg daily) 1
- Takes approximately 6-12 weeks to demonstrate separation from placebo 2
2. Treatment of Schizophrenia
- Approved for adults with schizophrenia 1
- Dosing: Start at 1 mg daily for Days 1-4, increase to 2 mg on Days 5-7, then can increase to maximum 4 mg based on response (target dose 2-4 mg daily) 1
- Demonstrated significant improvements in PANSS total scores (mean difference -5.76 points vs placebo) and CGI-S scores 3
- Lower discontinuation rates compared to placebo, with akathisia being the most common extrapyramidal symptom 3
Recently Approved Indication (2023)
3. Agitation in Alzheimer's Disease Dementia
- First and only FDA-approved medication specifically for agitation associated with dementia due to Alzheimer's disease 2, 4, 5
- Dosing: 2-3 mg daily shows efficacy 5, 6
- Demonstrated approximately 5-point greater reduction on Cohen-Mansfield Agitation Inventory (CMAI) at week 12 versus placebo 5
- Critical timing consideration: Requires 6-12 weeks to become effective; not for PRN/"as needed" use 2, 5
- Black box warning: Increased mortality risk when using antipsychotics in elderly patients with dementia-related psychosis 4
- Particularly beneficial for patients with severe agitation/aggression 2
- Works with or without concomitant antidepressants 7
Mechanism of Action
Brexpiprazole is a serotonin-dopamine activity modulator with:
- Partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors
- Antagonist activity at 5-HT2A receptors and noradrenergic α1B and α2C receptors 8, 9
Important Dosing Modifications
Dose reductions required for 1:
- CYP2D6 poor metabolizers: Use half the recommended dose
- Moderate-severe hepatic impairment: Maximum 2 mg daily (MDD) or 3 mg daily (schizophrenia)
- Renal impairment (CrCl <60 mL/min): Maximum 2 mg daily (MDD) or 3 mg daily (schizophrenia)
- Strong CYP2D6 or CYP3A4 inhibitors: Use half the recommended dose
- Both strong CYP2D6 AND CYP3A4 inhibitors: Use quarter of recommended dose
- Strong CYP3A4 inducers: Double the dose over 1-2 weeks
Context Within Treatment Guidelines
The 2025 INTEGRATE schizophrenia guidelines 10 emphasize antipsychotic monotherapy as the standard approach, with polypharmacy (including brexpiprazole combinations) reserved for specific situations such as treatment-resistant cases or clozapine augmentation. Combining aripiprazole (a similar D2 partial agonist) with clozapine may reduce side effects or residual symptoms 11, suggesting brexpiprazole might serve a similar augmentation role, though this is not yet established in guidelines.